Differences in susceptibility to ADR nephropathy among C57BL/6 substrains

Area of Science:

• Nephrology
• Animal Models
• Chronic Kidney Disease Research

Background:

• Adriamycin (ADR) nephropathy is a key mouse model for studying chronic kidney disease (CKD) mechanisms.
• Standard C57BL/6J mice do not develop ADR nephropathy, limiting research scope.
• Previous reports suggest C57BL/6N mice are susceptible, but require further investigation.

Purpose of the Study:

• To confirm ADR susceptibility in C57BL/6N mice.
• To compare ADR nephropathy development between C57BL/6NCrl and C57BL/6NJcl substrains.
• To evaluate the impact of ADR administration route on nephropathy severity.

Main Methods:

• Administration of Adriamycin (ADR) to C57BL/6NCrl and C57BL/6NJcl mice.
• Assessment of nephropathy through monitoring albuminuria and mesangial cell proliferation.
• Comparison of ADR administration via tail vein versus orbital vein.

Main Results:

• C57BL/6NCrl mice exhibited significant albuminuria and mesangial cell proliferation, indicating ADR nephropathy.
• C57BL/6NJcl mice did not develop ADR-induced nephropathy symptoms.
• ADR administration via the tail vein resulted in more severe nephropathy than via the orbital vein.

Conclusions:

• C57BL/6NCrl mice are a suitable strain for ADR-induced nephropathy models.
• ADR nephropathy severity is influenced by the route of administration.
• Orbital vein administration leads to milder ADR nephropathy compared to tail vein administration.